Showing 2331-2340 of 5696 results for "".
- Aviceda Announces Additional Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmologyhttps://modernod.com/news/aviceda-announces-additional-members-to-its-clinical-advisory-board-to-support-its-clinical-development-strategy-in-ophthalmology/2481232/Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators, announced the addition of ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are:
- Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patientshttps://modernod.com/news/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectiveness-of-the-omni-surgical-system-in-pseudophakic-glaucoma-patients-with-uncontrolled-pressure-following-a-previous-combination-cataract-stent-procedure/2481221/Sight Sciences announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophaki
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- EyeCare Partners Expands Footprint in Northern Ohio with Three Additional Practiceshttps://modernod.com/news/eyecare-partners-expands-footprint-in-northern-ohio-with-three-additional-practices/2481171/EyeCare Partners announced that it has expanded its presence in Northern Ohio through a partnership with Novus Clinic, Corrective Eye Center, and Retina Specialists of Ohio (RSO). Additionally, the company plans to build a new Ambulatory Surgery Center (ASC) as well as a 16-exam lane clinic,
- SpyGlass Pharma Presents 3-Month Data from the First-In-Human Trial of Its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-presents-3-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481140/SpyGlass Pharma announced 3-month data from a first-in-human glaucoma treatment trial showing that its breakthrough drug delivery platform lowered IOP in patients with open-angle glaucoma or ocular hypertension. The data were showcased during an oral presentation at the Eyecelerator inn
- Trefoil Therapeutics Announces Positive Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgeryhttps://modernod.com/news/trefoil-therapeutics-announces-positive-phase-2-study-data-showing-corneal-regeneration-and-vision-recovery-following-descemet-stripping-only-dso-surgery/2481137/Trefoil Therapeutics announced positive phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). TTHX1114, a proprietary engineered fibroblast growth factor-1 (FGF1) variant, is delivered as an intracameral injection into the anterior chamber of the eye. Most
- Iridex to Showcase its Non-Incisional Treatments for Glaucoma and Introduce Sweep Management Software at AAO 2022https://modernod.com/news/iridex-to-showcase-its-non-incisional-treatments-for-glaucoma-and-introduce-sweep-management-software-at-aao-2022/2481130/Iridex will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software, and host 8 physician presentations at the 2022 American Academy of Ophthalmology (AAO) annual meeting in Chicago, September 30 – October 3. MicroPulse Transscleral Laser Thera
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w
- Eye PCR to Present Poster Presentations on Fixoflex, a New Intraocular Ophthalmic Implant Designed to Hold an IOL Inside Capsular Baghttps://modernod.com/news/eye-pcr-to-present-poster-presentations-on-fixoflex-a-new-intraocular-ophthalmic-implant-designed-to-hold-an-iol-inside-capsular-bag/2481087/At the ESCRS meeting in Milan, Italy, Eye PCR will provide Poster Presentations on Fixoflex, a new intraocular ophthalmic implant designed to hold an IOL minimizing any decentration and tilt inside of the eye’s natural capsular bag. According to Amsterdam-based Eye PCR,